This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing a public meeting entitled “Adenoviral Vector Safety” and a workshop of the “Adenoviral Standards Working Group.” The purpose of the public meeting and workshop is to discuss the scientific and technological issues related to developing voluntary industry reference standards for adenoviral vectors used to deliver human gene therapies. The voluntary industry reference standards will be used to help ensure the safety of adenoviral vectors intended for use in humans.
Date and Time: The public meeting and workshop will be held on February 1, 2001. The Adenoviral Vector Safety meeting will be held from 9:30 a.m. to 12 noon.
The Adenoviral Standards Working Group workshop will be held from 1 p.m. to 5 p.m.
Location: The Adenoviral Vector Safety meeting will be held at the Wilson Auditorium, National Institutes of Health, Bldg. 1, 8600 Rockville Pike, Bethesda, MD 20894.
The Adenoviral Standards Working Group workshop will be held at the National Institutes of Health, Bldg. 29B, Conference Rooms A, B, and C, 8600 Rockville Pike, Bethesda, MD 20894.
Contact: Steven R. Bauer, Center for Biologics Evaluation and Research (HFM-521), Food and Drug Administration, Bldg. 29B, rm. 2NN11, Bethesda, MD 20894, 301-827-0684, FAX 301-827-0449, or e-mail: email@example.com.
Registration: Mail or fax your registration information (including name, title, firm name, address, telephone, fax number, and e-mail address) to Steven R. Bauer (address above) by Friday, January 19, 2001. There is no registration fee for the meeting or workshop. Seating is limited, therefore, interested parties are encouraged to register early. Registration at the site will be done on a space available basis on the day of the meeting and workshop, beginning at 8:30 a.m. If you need special accommodations due to a disability, please contact Steven R. Bauer at least 7 days in advance.
Agenda: The Adenoviral Vector Safety meeting will provide a forum for all members of the public to express their concerns about adenoviral vector safety and explore alternatives for enhancing the safety of adenoviral vectors.
The Adenoviral Standards Working Group workshop is cosponsored by FDA’s Center for Biologics and Research (CBER) and the Williamsburg BioProcessing Foundation. The workshop will be of primary interest to public health professionals developing new human gene therapy products and manufacturers contemplating the production of such products. The objectives of the workshop are to: (1) Select adenoviruses to use as voluntary reference standards for adenoviral vectors used for human gene therapy products; (2) describe the conditions and facilities to be used when producing bulk quantities of a voluntary reference standard; (3) establish characterization protocols for voluntary reference standards; and (4) address other issues related to voluntary reference standards for adenoviral vectors.
Transcripts: Transcripts of the Adenoviral Vector Safety meeting may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page. The transcript will also be available on the Internet at http://www.fda.gov/cber/minutes/workshop-min.htm.End Preamble Start Supplemental Information Start Signature
Dated: December 29, 2000.
Margaret M. Dotzel,
Associate Commissioner for Policy.
[FR Doc. 01-531 Filed 1-8-01; 8:45 am]
BILLING CODE 4160-01-S